Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KYMBERLY BROOKE MOYER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1295199933
CMS profile
4218244
Location
GALLATIN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,959.97

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,350.91 8
Food and Beverage $609.06 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $2,959.97 11

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KYMBERLY BROOKE MOYER

NPI 1295199933 · CMS profile ID 4218244

Allopathic & Osteopathic Physicians / Family Medicine

GALLATIN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295199933?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KYMBERLY BROOKE MOYER, NPI 1295199933, CMS profile ID 4218244. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295199933?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KYMBERLY BROOKE MOYER, NPI 1295199933, CMS profile ID 4218244. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295199933?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KYMBERLY BROOKE MOYER, NPI 1295199933, CMS profile ID 4218244, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1295199933?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $2,959.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $28.6009/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981405 CMS
ModernaTX, Inc. $36.0009/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981449 CMS
ModernaTX, Inc. $255.4609/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981397 CMS
ModernaTX, Inc. $323.5009/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981433 CMS
ModernaTX, Inc. $272.9609/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981417 CMS
ModernaTX, Inc. $214.6209/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981425 CMS
ModernaTX, Inc. $895.7907/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981325 CMS
ModernaTX, Inc. $150.0007/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981341 CMS
ModernaTX, Inc. $297.7207/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981353 CMS
ModernaTX, Inc. $325.0007/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981373 CMS
ModernaTX, Inc. $160.3207/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $2,959.97 11
PY2024 $87.60 4
PY2025 $179.85 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $704,529.61 86
PY2024 Recipient $12,465.00 2
PY2024 Principal investigator $2,124,816.60 102
PY2023 Principal investigator $2,430,274.77 2,115
PY2022 Principal investigator $630,109.32 1,010

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $945.78 12/30/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137350
Principal investigator 1 ModernaTX, Inc. $600.00 12/24/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137338
Principal investigator 1 ModernaTX, Inc. $75.13 12/23/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137258
Principal investigator 1 ModernaTX, Inc. $63,730.75 12/23/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137396
Principal investigator 1 ModernaTX, Inc. $33,607.85 12/19/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147137370
Principal investigator 1 ModernaTX, Inc. $87,818.95 12/19/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137382
Principal investigator 1 ModernaTX, Inc. $170.75 12/11/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137256
Principal investigator 1 ModernaTX, Inc. $16,568.31 12/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136194
Principal investigator 1 ModernaTX, Inc. $12,017.34 11/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137232
Principal investigator 1 ModernaTX, Inc. $111,473.95 11/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137244
Principal investigator 1 ModernaTX, Inc. $68.30 11/18/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137190
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/06/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136130
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/06/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136132
Principal investigator 1 ModernaTX, Inc. $1,650.00 11/06/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136134
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147136096
Principal investigator 1 ModernaTX, Inc. $750.00 11/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147136098
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147136100
Principal investigator 1 ModernaTX, Inc. $68.30 10/29/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137074
Principal investigator 1 ModernaTX, Inc. $1,835.40 10/23/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147136038
Principal investigator 1 ModernaTX, Inc. $170.75 10/14/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137072
Principal investigator 1 ModernaTX, Inc. $11,076.86 10/09/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147136040
Principal investigator 1 ModernaTX, Inc. $204.90 10/09/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147137070
Principal investigator 1 ModernaTX, Inc. $1,216.95 10/07/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137144
Principal investigator 1 ModernaTX, Inc. $900.00 10/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137132
Principal investigator 1 ModernaTX, Inc. $200.00 10/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147137170
Principal investigator 1 ModernaTX, Inc. $400.00 10/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147137172
Principal investigator 1 ModernaTX, Inc. $300.00 10/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136072
Principal investigator 1 ModernaTX, Inc. $10,246.82 09/25/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137034
Principal investigator 1 ModernaTX, Inc. $4,200.00 09/19/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147137052
Principal investigator 1 ModernaTX, Inc. $14,497.84 09/18/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147137006
Principal investigator 1 ModernaTX, Inc. $399.12 09/17/2024 Non-covered Recipient Entity
DELRICHT LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147136928
Principal investigator 1 ModernaTX, Inc. $5,600.00 09/16/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136986
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/11/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147135944
Principal investigator 1 ModernaTX, Inc. $2,800.00 09/11/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147135946
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/11/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147135948
Principal investigator 1 ModernaTX, Inc. $300.00 09/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147135950
Principal investigator 1 ModernaTX, Inc. $325.00 09/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147135952
Principal investigator 1 ModernaTX, Inc. $5,448.62 09/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135966
Principal investigator 1 ModernaTX, Inc. $9,950.00 09/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135968
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135970
Principal investigator 1 ModernaTX, Inc. $1,800.00 09/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135972
Principal investigator 1 ModernaTX, Inc. $800.00 09/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135974
Principal investigator 1 ModernaTX, Inc. $400.00 09/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147137042
Principal investigator 1 ModernaTX, Inc. $6,000.00 09/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147135942
Principal investigator 1 ModernaTX, Inc. $20,346.33 09/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147136020
Principal investigator 1 ModernaTX, Inc. $128,995.92 09/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136966
Principal investigator 1 ModernaTX, Inc. $300.00 08/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135900
Principal investigator 1 ModernaTX, Inc. $150.00 08/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135902
Principal investigator 1 ModernaTX, Inc. $600.00 08/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135904
Principal investigator 1 ModernaTX, Inc. $300.00 08/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135906
Principal investigator 1 ModernaTX, Inc. $300.00 08/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135910
Principal investigator 1 ModernaTX, Inc. $1,100.00 08/20/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136906
Principal investigator 1 ModernaTX, Inc. $900.00 08/09/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136910
Principal investigator 1 ModernaTX, Inc. $27,170.40 08/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136876
Principal investigator 1 ModernaTX, Inc. $43,997.20 07/29/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136342
Recipient Becton, Dickinson and Company $1,925.00 07/24/2024 Covered Recipient Physician Veritor COVID Professional No dispute reported 06/30/2026 1130725538
Principal investigator 1 ModernaTX, Inc. $200.00 07/04/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136338
Principal investigator 1 ModernaTX, Inc. $69,856.61 06/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136836
Recipient Becton, Dickinson and Company $10,540.00 06/16/2024 Covered Recipient Physician Veritor COVID Professional No dispute reported 06/30/2026 1130725530
Principal investigator 1 ModernaTX, Inc. $116,601.61 06/10/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136816
Principal investigator 1 ModernaTX, Inc. $2,600.00 06/05/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136796
Principal investigator 1 ModernaTX, Inc. $423.47 05/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136736
Principal investigator 1 ModernaTX, Inc. $325.00 05/24/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135748
Principal investigator 1 ModernaTX, Inc. $850.00 05/15/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136718
Principal investigator 1 ModernaTX, Inc. $6,352.05 05/09/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136702
Principal investigator 1 ModernaTX, Inc. $600.00 05/08/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136674
Principal investigator 1 ModernaTX, Inc. $400.00 05/08/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136768
Principal investigator 1 ModernaTX, Inc. $240.00 05/06/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136672
Principal investigator 1 ModernaTX, Inc. $4,238.65 05/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135718
Principal investigator 1 ModernaTX, Inc. $300.00 05/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136696
Principal investigator 1 ModernaTX, Inc. $10,000.00 05/01/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147135702
Principal investigator 1 ModernaTX, Inc. $2,300.00 04/29/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136642
Principal investigator 1 Becton, Dickinson and Company $4,250.00 04/28/2024 Non-covered Recipient Entity
Magnolia Family Medicine
Veritor COVID Professional No dispute reported 06/30/2026 1130725642
Principal investigator 1 ModernaTX, Inc. $200.00 04/17/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136650
Principal investigator 1 ModernaTX, Inc. $25,433.95 03/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136596
Principal investigator 1 ModernaTX, Inc. $167.50 03/27/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136490
Principal investigator 1 ModernaTX, Inc. $1,040.00 03/25/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136580
Principal investigator 1 ModernaTX, Inc. $152,925.43 03/22/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135630
Principal investigator 1 ModernaTX, Inc. $58,516.98 03/21/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136502
Principal investigator 1 ModernaTX, Inc. $61,712.78 03/21/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136560
Principal investigator 1 ModernaTX, Inc. $45,922.23 03/21/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136614
Principal investigator 1 ModernaTX, Inc. $300.00 03/08/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136610
Principal investigator 1 ModernaTX, Inc. $8,681.13 03/06/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136540
Principal investigator 1 ModernaTX, Inc. $440.00 02/29/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136380
Principal investigator 1 ModernaTX, Inc. $300.00 02/28/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136474
Principal investigator 1 ModernaTX, Inc. $119,571.23 02/26/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136460
Principal investigator 1 ModernaTX, Inc. $300.00 02/21/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136444
Principal investigator 1 ModernaTX, Inc. $600.00 02/16/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136434
Principal investigator 1 ModernaTX, Inc. $6,202.14 02/14/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147135608
Principal investigator 1 ModernaTX, Inc. $600.00 02/07/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136354
Principal investigator 1 ModernaTX, Inc. $2,400.00 02/07/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136402
Principal investigator 1 ModernaTX, Inc. $26,640.46 02/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135602
Principal investigator 1 ModernaTX, Inc. $300.00 01/31/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136242
Principal investigator 1 ModernaTX, Inc. $6,597.48 01/29/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136234
Principal investigator 1 ModernaTX, Inc. $300.00 01/24/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135544
Principal investigator 1 ModernaTX, Inc. $3,731.30 01/24/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136280
Principal investigator 1 ModernaTX, Inc. $548,582.73 01/18/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136306
Principal investigator 1 ModernaTX, Inc. $871.13 01/17/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147135502
Principal investigator 1 ModernaTX, Inc. $33,883.64 01/16/2024 Non-covered Recipient Entity
DELRICHT LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147136264
Principal investigator 1 ModernaTX, Inc. $425.60 01/10/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136302
Principal investigator 1 ModernaTX, Inc. $96,261.06 01/05/2024 Non-covered Recipient Entity
DELRICHT LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147135536
Principal investigator 1 ModernaTX, Inc. $600.00 01/05/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136226
Principal investigator 1 ModernaTX, Inc. $57,194.92 01/03/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147136222
Principal investigator 1 ModernaTX, Inc. $300.00 01/02/2024 Non-covered Recipient Entity
DELRICHT LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147136284